KRAS and lung adenocarcinoma: We aimed to develop radiomic and clinical-radiomic models to predict: (i) actionable tumor molecular alteration, focusing on EGFR and KRAS mutations, and ALK gene rearrangement and (ii) patients’ overall survival (OS), exploring whether radiomics can add useful information for physicians’ decisions before and during the treatment of patients with advanced lung adenocarcinoma.